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Abstract
Alpha-mannosidosis is an inherited lysosomal storage disorder characterized by immune deficiency,
facial and skeletal abnormalities, hearing impairment, and intellectual disability. It occurs in
approximately 1 of 500,000 live births. The children are often born apparently normal, and their
condition worsens progressively. Some children are born with ankle equinus or develop
hydrocephalus in the first year of life. Main features are immune deficiency (manifested by recurrent
infections, especially in the first decade of life), skeletal abnormalities (mild-to-moderate dysostosis
multiplex, scoliosis and deformation of the sternum), hearing impairment (moderate-to-severe
sensorineural hearing loss), gradual impairment of mental functions and speech, and often, periods
of psychosis. Associated motor function disturbances include muscular weakness, joint
abnormalities and ataxia. The facial trait include large head with prominent forehead, rounded
eyebrows, flattened nasal bridge, macroglossia, widely spaced teeth, and prognathism. Slight
strabismus is common. The clinical variability is significant, representing a continuum in severity.
The disorder is caused by lysosomal alpha-mannosidase deficiency. Alpha-mannosidosis is inherited
in an autosomal recessive fashion and is caused by mutations in the MAN2B1 gene located on
chromosome 19 (19 p13.2-q12). Diagnosis is made by measuring acid alpha-mannosidase activity in
leukocytes or other nucleated cells and can be confirmed by genetic testing. Elevated urinary
secretion of mannose-rich oligosaccharides is suggestive, but not diagnostic. Differential diagnoses
are mainly the other lysosomal storage diseases like the mucopolysaccharidoses. Genetic
counseling should be given to explain the nature of the disease and to detect carriers. Antenatal
diagnosis is possible, based on both biochemical and genetic methods. The management should be
pro-active, preventing complications and treating manifestations. Infections must be treated
frequently. Otolaryngological treatment of fluid in the middle ear is often required and use of
hearing aids is invariably required. Early educational intervention for development of social skills is
needed and physiotherapy is important to improve bodily function. Orthopedic surgery may be
necessary. The long-term prognosis is poor. There is an insidiously slow progression of
neuromuscular and skeletal deterioration over several decades, making most patients wheel-chair
dependent. No patients manage to be completely socially independent. Many patients are over 50
years of age.
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Orphanet Journal of Rare Diseases 2008, 3:21 http://www.ojrd.com/content/3/1/21Disease name and synonyms
α-Mannosidosis, Lysosomal α-D-Mannosidase Defi-
ciency, α-Mannosidase B Deficiency. OMIM 248500.
History
Hurler-like syndrome had been known for a number of
years when the Swedish physician Öckerman in Lund
described a 4 year old boy with a Hurler-like phenotype in
1967 [1]. He died at the age of 4 from pneumonia, and in
his tissues appeared large amounts of oligosaccharide
material with the dominance of mannose. Therefore, the
term "Mannosidosis" was suggested as the name of the
disorder [2]. In 1977 Loeb described an atypical form of
mucopolysaccharidosis which later turned out to be α-
mannosidosis [3].
In 1978, Gideon Bach described two Palestinian siblings
with a mild clinical phenotype and residual mannosidase
activity, which increased by 40% with the addition of zinc
(Zn++) to cell extracts of both patients and control subjects
[4]. It took 25 years before the molecular mechanism of
this observation could be explained [5]. Meanwhile, this
observation led to many therapeutic attempts with zinc
substitution in cattle [6] and man [7], which all proved
futile.
Since these early clinical descriptions, many research
groups have contributed to the characterization of the
enzyme and the corresponding gene in several species
such as human, cow, cat, mouse and guinea pig. Further-
more, underlying genetic, biochemical and physiological
mechanisms of the disease have been explored, and addi-
tional clinical aspects of the disease such as immunodefi-
ciency and psychiatric complications of the disease have
been described (see below). Subsequently, two EU
Research Consortiums, EURAMAN 2002–2005 (A sys-
tematic and multidisciplinary approach towards under-
standing and therapy of the inborn lysosomal storage
disease α-mannosidosis), and HUE-MAN 2006–2009
(Towards the Development of an Effective Enzyme
Replacement Therapy for Human α-Mannosidosis) were
established [8].
Definition and diagnosis criteria
Alpha-mannosidosis is a genetic disorder of metabolism
characterized by immune deficiency, facial and skeletal
abnormalities, hearing impairment, and mental retarda-
tion. The disorder is caused by lysosomal α-mannosidase
deficiency and is inherited in an autosomal recessive fash-
ion.
Elevated urinary secretion of mannose-rich oligosaccha-
rides is suggestive, but not diagnostic for α-mannosidosis.
Diagnosis is made by measuring acid α-mannosidase
activity in leukocytes or other nucleated cells, e.g. fibrob-
lasts. Genetic diagnostics by mutation analysis is available
from a few laboratories.
Alpha-mannosidosis has been described as two distinct
phenotypes: one severe form with hepatomegaly and
early death following severe infections (Type I), and a
mild form with hearing loss, mental retardation, and sur-
vival into adulthood (Type II) [4,9,10].
However, when studying published cases, the patients
present a continuum of clinical presentations, many of
which probably can be influenced by background genetics
or external factors like infectious diseases, educational
opportunities, proactive initiatives, and quality of health
services [11-13].
At present, three clinical types have been suggested [14-
16]: Type 1: Mild form clinically recognized after 10 years
of age, without skeletal abnormalities and very slow pro-
gression; Type 2: Moderate form, clinically recognized
before 10 years of age, with skeletal abnormalities, and
slow progression with development of ataxia at age 20–
30; Type 3: Severe form, immediately recognized, with
skeletal abnormalities, and obvious progression, leading
to an early death from primary central nervous system
(CNS) involvement or myopathy (Table 1). Most patients
belong to clinical type 2.
Epidemiology
The prevalence of the disease is not precisely known. A
study from Norway reported six (later eight) patients in a
population of 4.5 millions [17]. This corresponds with a
Table 1: Clinical types of alpha-mannosidosis
Type II: Less severe, late onset form involving hearing loss, 
coarse face, mental retardation, and hepatosplenomegaly.
Type I: Severe infantile form which is fatal at 
<3–8 years of age.
Type 1: Mild form clinically, recognized after 10 years of age, 
without skeletal abnormalities and very slow progression.
Type 2: Moderate form, clinically recognized 
before 10 years of age, with skeletal 
abnormalities, and slow progression with 
development of ataxia at age 20–30.
Type 3: Severe form, 
immediately recognized, with 
skeletal abnormalities, and 
obvious progression, leading to 
an early death from primary 
CNS involvement or myopathy.
Staging of disease severity of mannosidosis according to Desnick et al., 1976 [9] (Upper panel) and according to Chester et al., 1982 and Malm & 
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in 500,000 live births [18]. Mannosidosis is expected to
be found in any ethnic group anywhere in the world.
Clinical description
Alpha-mannosidosis should be suspected in individuals
with mental retardation, skeletal changes, hearing loss,
and recurrent infections. The children are often born
apparently normal, and their condition worsens progres-
sively. Therefore, early diagnosis is important if bone mar-
row transplantation (BMT) is to be considered a
therapeutic modality. Since inborn errors of lysosomal
metabolism occur in approximately 1:5,000 live births,
many have argued for screening of newborns for early
diagnosis and initiation of treatment [18].
Onset of symptoms
Early references have described that early psychomotor
development appears normal, and that pathophysiology
develops over time [4,19]. However, some children are
born with ankle equinus or develop hydrocephalus in the
first year of life [17,20].
In α-mannosidosis guinea pigs, long before the onset of
obvious neurologic abnormalities at 2 months, cerebral
pathophysiology like neuronal lysosomal vacuolation,
and reduced myelination of white matter was observed.
Thus, complex neuropathologic changes in α-mannosido-
sis guinea pigs are already present at birth, long before
clinical changes are evident, and similar events are likely
to occur in humans with this disorder [21].
Associated facial features
Facial traits may be subtle, but independent of race and
background genetics, all patients have some degree of
coarse Hurler-like features. This is classically a large head
with prominent forehead, rounded eyebrows, flattened
nasal bridge, macroglossia, widely spaced teeth, and prog-
nathism. The neck is usually short (Fig 1).
Associated skeletal abnormalities
According to Chester (1982), clinical or radiographic
signs of mild-to-moderate dysostosis multiplex are
present in 90% of the patients [14]. The most frequent
abnormalities are scoliosis and deformation of the ster-
num [22] (Fig 2). These changes are present at birth. Genu
valgus (knucle knee) is common and, like the same com-
plication in Gaucher disease, may be treated with epiphy-
seal arthrodesis at a young age before the epiphyseal
lineation of the knee is closed [23]. Over time, from the
second till the fourth decade of life the patients may
develop destructive polyarthropathy, especially coxar-
throsis (Fig 3), but also gonarthrosis [24,25]. These are
often so serious that orthopedic corrections are needed
[26]. Patellar bilateral dislocation and severe synovial
hypertrophy have also been described along with Charcot
elbow and bilateral hip and elbow avascular necrosis in
one patient [27].
Associated hearing impairment
Moderate or severe sensorineural hearing loss seems inev-
itable [12,22,28,29]. It is regularly worsened by otitis or
accumulation of fluid in the middle ear, adding a
mechanical component to the hearing deficit [17].
Associated ocular changes
Slight strabismus is common and also hyperopia more
frequently than myopia [14,30]. Blurred discs [31], super-
Facial features in alpha-mannosidosisigure 1
Facial features in alpha-mannosidosis. A. Twins aged 18 
Months. Note enlarged head, short neck, rounded eyebrows, 
saddle nose, and prominent forehead. B. Same twins aged 8 
years. Note slight muscular atrophy of the hands. C. Boy, 
aged 27. Note: Hearing aid.
Radiography of kyphoscoliosis in alpha-mannosidosis before an  after orthopedic correctionFigure 2
Radiography of kyphoscoliosis in alpha-mannosidosis 
before and after orthopedic correction. A. Kyphoscol-
iosis with skeletal abnormalities of all vertebrae. B. Ortho-
pedic correction of kyphosis.Page 3 of 10
(page number not for citation purposes)
Orphanet Journal of Rare Diseases 2008, 3:21 http://www.ojrd.com/content/3/1/21ficial corneal opacities, and lenticular changes seem to be
rare but have been reported [4].
Associated mental retardation
As soon as the age of the patients makes intelligence quo-
tient (IQ) measurements feasible, almost all patients
show some degree of mental retardation. In a clinical
study that included eight patients the age at onset of
symptoms varied from 6 months to 3 years [10]. The first
symptom was usually delayed development of speech or
motor or mental functions. All the patients were mildly or
moderately mentally retarded with an IQ of 60–80, with
a declining tendency over later decades. With their poor
ability to speak combined with sensorineural hearing loss,
patients score generally better in nonverbal tests [10].
Although some have suggested the disease stabilises in
puberty [32], most follow-up observations suggest grad-
ual impairment of mental and motor functions and
speech with age. Longitudinal assessments of three broth-
ers have been done by testing of general intelligence, lan-
guage, visual spatial skills, and overall adaptive abilities
over two years. During the follow-up, the cognitive find-
ings showed that the patients manifested mild cognitive
deficits. Cognitive deficits were generally uniform with no
signs of progressive deterioration, except receptive lan-
guage abilities [33]. Other patients are described as having
profound retardation even at young age [19,34]. Again,
there can be remarkable differences in mental functioning
among siblings [28,35,36].
Patients learn to speak late, sometimes in the second dec-
ade of life. This impaired development of language with
limited vocabularies and poor pronunciation might be
explained by their congenital and/or later-onset hearing
loss. Many patients learn to read, but have difficulties in
understanding abstracts (Malm D: personal observation).
Associated motor function disturbances
The development of motor functions in affected patients
is generally slow, and the children appear clumsy. This is
caused by a combination of factors like muscular weak-
ness, joint abnormalities and ataxia due to cerebral atro-
phy and cerebral demyelination [37].
The impairment is by nature progressive, with gradual
worsening in the second and third decade of life [10].
However, as for mental retardation, there is a considerable
variation in the clinical progression and in a long term
observation of two patients, no progression of neurologi-
cal function has been noted [28], whereas some investiga-
tors have suggested that the disease progression is halted
after puberty [32]. Additional studies on the natural
course of the disease are needed.
Associated psychiatric disease
In intellectually disabled patients, psychiatric symptoms
may be overlooked. However, a systematic survey found
psychiatric symptoms in more than 25% of adult patients
with mannosidosis [38]. It typically presented in adoles-
cence or early adulthood. In mentally retarded patients,
psychiatric symptoms form part of a more diffuse clinical
picture with systemic, cognitive or motor neurological
signs. It can present with acute and recurrent attacks of
confusion, sometimes with anxiety, depressions or, hallu-
cinations. These might be associated with loss of function,
like decreased appetite with severe weights loss or incon-
tinence for urine and feces. The periods of psychosis usu-
ally last 3 to 12 weeks, followed by a long period of
hypersomnia and sometimes loss of abilities, like diffi-
culty speaking or inability to read. Search for organic
causes has been negative [38]. As specific treatments
should be more effective at the initial stage before the
occurrence of irreversible neurological lesions, clinicians
should be aware of atypical psychiatric symptoms in
patients with inborn errors of metabolism [39].
Associated immunodeficiency and autoimmunity
Mannosidosis patients suffer from recurrent infection,
especially in the first decade of life. In one single patient,
impaired leukocyte chemotaxis and reduced phagocytosis
were found [9]. Malm and co-workers compared the
humoral and cellular immunological functioning in six
patients to that of six age- and sex-matched healthy con-
trols [40]. They found that post-immunization levels of
antibody were lower in patients, proving a decreased abil-
ity to produce specific antibodies after antigen presenta-
tion. More interestingly, there was a serum factor in
patient plasma, inhibiting phagocytosis [40]. In mannosi-
dosis, there are increased levels of oligosaccharides in
plasma [41]. Oligomannosides with five and six mannose
residues bind to interleukin-2 (IL-2) receptors disturbing
the IL-2-dependent responses [42]. IL-2 activates T-, B-,
and NK cells. It can therefore be speculated that blockage
of this receptor is the mechanism causing the immune
deficiency seen in mannosidosis.
Coxarthrosis in alpha-mannosidosisFigure 3
Coxarthrosis in alpha-mannosidosis. A. Coxarthrosis at 
8 years of age. B. Progression of coxarthrosis at age 13.Page 4 of 10
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prevalence of autoimmune disorders among mannosido-
sis patients ([13] and Malm D: personal observations).
Interestingly, in a mice model, alpha-mannosidase II defi-
ciency reduces complex-type N-glycan branching and
induces an autoimmune disease similar to human sys-
temic lupus erythematosus (SLE) with induction of anti-
nuclear antibodies with reactivity towards histone, Sm
antigen, and DNA [43].
Associated renal and cardiac complications
End-stage kidney failure has been reported only once,
where an Italian patient successfully received a kidney
transplant [44]. In a study in mannosidosis mice, deposits
of storage material in myocardium were reduced after
enzyme replacement [45]. In some case descriptions, a
murmur of the heart is mentioned, but so far, reports on
manifest heart disease have not been reported.
Molecular etiology
During normal turnover and catabolism glycoproteins are
digested by proteinases and glycosidases within the lyso-
somes. These enzymes degrade glycoproteins into frag-
ments small enough to be excreted or transported to the
cytosol for reuse. Lack or deficiency of such hydrolases
results in the multi-systemic accumulation of undigested
material in the lysosomes. Consequently, the lysosomes
swell resulting in severe impairment of cellular functions
(Fig 4). However, the pathophysiology of lysosomal stor-
age disorders is complex, and accumulation of storage
material alone cannot fully explain the cause of disease.
Lysosomal α-mannosidase is an exoglycosidase which
cleaves the α-mannosidic linkages during the ordered deg-
radation of N-linked oligosaccharides. The enzyme has
the capacity to cleave α(1 → 2), α(1 → 3) and α(1 → 6)
mannosidic linkages found in high mannose and hybrid
type glycans [46,47]. Deduced from the analyses of man-
nose rich fractions from urine of affected individuals the
major lysosomal storage products are the oligosaccha-
rides:
Man(α1 → 3)Man(β1 → 4)GlcNac, Man(α1 →
2)Man(α1 → 3)Man(β1 → 4)GlcNac and Man(α1 →
2)Man(α1 → 2)Man(α1 → 3)Man(β1 → 4)GlcNac [48].
However, several additional, but apparently less abun-
dant urinary oligosaccharides have been identified [49],
all of them with GlcNac at the reducing end (reviewed by
[50]).
Alpha-mannosidosis is caused by mutations in the
MAN2B1 (LAMAN) gene encoding lysosomal α-mannosi-
dase. The MAN2B1 is located on chromosome 19
(19p13.2-p13.11) and is composed of 24 exons spanning
21.5 kb [51,52]. The MAN2B1 mRNA has the capacity to
encode a polypeptide of 988 [53] or 1011 [54] amino
acids depending on the start site of translation (Genebank
accession numbers U68382/U68567 and U60266.1). As
judged by Northern blot analyses, the level of MAN2B1
expression appears to be highest in lung [54], kidney, pan-
creas [53,54], and peripheral blood leukocyte [53]. In
CNS the highest level of expression appears to be in cor-
pus callosum and spinal cord, whereas considerably lower
levels are observed in the larger structures, which include
cerebellum, cerebral cortex, frontal and temporal lobes
[54]. The significance (if any) of this variation is not clear.
The enzyme is synthesized as a single chain precursor that
is processed into three glycopeptides of 70, 42 and 15 kDa
[54]. In humans, the 70 kDa peptide is further partially
proteolysed into three more peptides that are joined by
disulfide bridges – constituting all together 5 peptides (a-
e) [54]. α-mannosidase contains 11 potential N-linked
glycosylation sites all of which are occupied with either
high mannose or complex type oligosaccharides [54].
Based on electron microscopy, X-ray diffraction data and
the structure of D. melanogaster Golgi II α-mannosidase,
the structure of the bovine lysosomal α-mannosidase was
resolved at 2.7 Å resolution [5]. α-mannosidase is a di-
mer and the 3-dimensional structure of bovine lysosomal
α-mannosidase (which shares 80% identity to its human
counterpart) nicely defines the fold of each peptide, iden-
tifies the active site and provide clues to understand lyso-
somal transport and low pH activation (Fig 5).
Furthermore, the 3-dimensional structure provides the
basis for understanding α-mannosidosis at the atomic
level.
Disease-causing mutations
A total of 40 different disease-causing mutations have
been reported over the last 10 years. Except for two unre-
Electron micrograph of a vacuolated lymphocyteFigu e 4
Electron micrograph of a vacuolated lymphocyte. 
Electron micrograph of a vacuolated lymphocyte from a man-
nosidosis patient (A) as compared to a lymphocyte from a 
normal control (B).Page 5 of 10
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gin [13,54,55], the patients studied originate from Europe
[11,15,54,56-60]. The genetic aberrations reported are
scattered all over the MAN2B1 gene and include missense,
nonsense, small and large deletions, small insertions and
splice site mutations. Most mutations are private as they
occur in single or in a few families only. However, mis-
sense mutation c.2248C>T resulting in the replacement of
arginine with tryptophane at amino acid position 750
(p.R750W) appears to be frequent among mannosidosis
patients, as it has been reported from most European pop-
ulations studied, accounting for more than 30% of all dis-
ease alleles detected by Berg et al. (1999) [15].
Haplotyping based on 5 internal single nucleotide poly-
morphisms (SNP) markers showed that a common haplo-
type was shared by Finnish, Polish and Italian
homozygotes, whereas a second haplotype, deviating at
one marker, was observed in a Turkish patient [15]. These
findings indicate that the frequency and wide geographi-
cal distribution of the "p.750W" allele may result both
from founder effects and from recurrent mutational
events. However, further analysis including patients of
other origins must be carried out in order to explore this
fully.
Altogether 12 missense mutations have been functionally
characterized by expression analysis in mammalian cell
lines followed by enzyme activity measurements and
modeling into the MAN2B1 3-dimensional structure. Mis-
sense mutations affect residues located in the active site, in
the dimer interphase as well as in the interior of the pro-
tein [5,58,59,61]. Based on pulse chase experiments and
immune fluorescence microscopy, Hansen et al. (2004)
monitored the intracellular transport of mutant enzymes.
They concluded that mutant enzymes (missense) could be
divided into two groups: Group 1 that was correctly sorted
to the lysosomes and group 2 that was retained (transport
arrested) in the endoplasmic reticulum (ER) [61].
Genotype phenotype relationships
There is no apparent correlation between MAN2B1 geno-
type and clinical phenotype in α-mannosidosis [15]. Clin-
ical variation within sib ships has been observed
[17,28,35,36], and patients characterized as less severely
or moderately affected were shown to be homozygous for
null mutations [15]. However, attempts to predict geno-
type/phenotype relationships often suffer from lack of
data. Case reports on clinical findings are few and often
include few patients and variability of methods used.
Likewise, mutation reports often lack sufficient clinical
data.
Enzyme activity measurements from patient leukocytes or
fibroblast cells provide no clue either to a MAN2B1 geno-
type/phenotype correlation as these values range from 5%
to 15% of normal levels. Using a refined method Berg et
al. (1999) demonstrated that the level of cross-reacting α-
mannosidase activity was less than 1.3% of that in con-
trols, with no consistent variation among affected individ-
uals. However, one cannot rule out the existence of
MAN2B1 genotypes ("mild" mutations) that cause sub-
clinical symptoms associated with residual enzyme activ-
ity. Such cases would likely escape detection as they will
not be severe enough to arouse the suspicion of α-man-
nosidosis.
Environmental factors and other genetic factors may con-
tribute to the clinical heterogeneity seen in α-mannosido-
sis. Environmental factors might be exposure to
pathogens causing recurrent infections and thereby wors-
ening of the disease symptoms. Other genetic factors
might be those that encode other mannosidases like
cytosolic α-mannosidase that potentially might contrib-
ute to the intra cellular clearance of undigested oligosac-
charides [14,41,62-64]. However, no such salvage
pathway has yet been proven to contribute to the clinical
variability.
The 3-dimensional structure of lysosomal α-mannosidaseFigure 5
The 3-dimensional structure of lysosomal α-mannosi-
dase. Peptides are coloured a-red, b-orange, c-yellow, d-
green and e-blue. The active site is denoted by a Zn++ ion. 
Two mutant sites are displayed, demonstrating the effect of 
mutations c.215A>T: p.H72L affecting Zn++ coordination in 
the actives site (group 1 mutation, see text for explanation) 
and the prevalent mutation c.2248C>T: p.R750W which is 
likely affecting peptide e-d interaction (group 2 mutation, see 
text for explanation). The figure was kindly provided by Dr. 
P. Heikinheimo, University of Helsinki, Finland. It has been 
prepared with the program PyMol [72].Page 6 of 10
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patients is warranted in order to explore the clinical varia-
bility of α-mannosidosis. Indeed, a study on the natural
history of mannosidosis was recently initiated by HUE-
MAN – a multinational research project supported by the
sixth framework program of the European Union [8].
Diagnostic methods
Peripheral blood examination
Light microscopy or transmission electron microscopy
(TEM) demonstrates vacuoles in bone marrow smears and
lymphocytes from peripheral blood in most affected indi-
viduals (Fig 4) (reviewed in [14]). Although detection of
vacuoles by microscopy is a useful screening test, supple-
mentary investigations are necessary when α-mannosido-
sis is suspected.
Oligosaccharides in urine
Elevated urinary excretion of mannose-rich oligosaccha-
rides can be demonstrated by thin-layer chromatography
[41] or high performance liquid chromatography (HPLC)
[65]. This finding is suggestive of α-mannosidosis, but not
diagnostic.
Acid α-mannosidase activity
The most efficient and reliable method of establishing the
diagnosis of α-mannosidosis is the assay of acidic α-man-
nosidase activity in leukocytes or other nucleated cells.
This fluorometric assay is performed at low pH (usually at
pH 4) with the substrate 4-methylumbelliferyl α-D-man-
nopyranoside. In affected individuals, acid α-mannosi-
dase enzyme activity in peripheral blood leukocytes is
5%–15% of normal activity. Residual enzyme activity
could possibly represent α-mannosidase activity from
other organelles or compartments (e.g., Golgi apparatus;
MAN2A1, cytosol; MAN2C1 or ER; MAN1B1), showing
some activity also at low pH. Following immunoprecipi-
tation with anti-acid α-mannosidase polyclonal antibod-
ies, acid α-mannosidase enzyme activity ranges from
0.1% to 1.3% of normal [15]. Such testing is not per-
formed routinely. In carriers, acid α-mannosidase enzyme
activity is usually 40%–60% of normal, and is therefore
unreliable for carrier detection because of the overlap
between carriers and non-carriers.
Genetic testing
Identification of disease causing mutations is carried out
on DNA from peripheral blood cells, by polymerase chain
reaction (PCR) amplification of all 24 MAN2B1 exons fol-
lowed by DNA sequencing.
Differential diagnosis
The main symptoms of mannosidosis, like dysmorphic
traits, dysostosis, and mental retardation, are shared with
the symptoms in many lysosomal storage diseases like
mucopolysaccharidosis.
Genetic counseling
According to autosomal recessive inheritance, offspring of
carrier parents have 25% risk of being affected whereas
50% will be non-symptomatic carriers.
Antenatal diagnosis
Prenatal testing is available for pregnancies of carrier par-
ents. Prenatal testing may be performed by analysis of acid
α-mannosidase enzyme activity in fetal cells obtained by
chorionic villus sampling at 10–12 weeks gestation or by
amniocentesis at 15–18 weeks. DNA from the same
sources can be used for mutation analysis. Preferably,
mutation analysis should be carried out in the parents in
advance of pregnancy. Genotype does not allow predic-
tion of severity of disease.
Management
Non-specific management
In general, the approach to the patients should be pro-
active, searching for emerging complications. After a full
physical examination, focusing on the known complica-
tions of mannosidosis like hydrocephalus, otitis media,
hearing loss, dental state, joint status, kyphoscoliosis, and
mental state, a plan should be made to limit the health
consequences for the patient.
This would also include examination by an ophthalmolo-
gist, an otolaryngologist, audiometry and neuropsycho-
logical assessment, blood tests, and skeletal evaluation
with radiographs, especially of the head, spine, knees or
other skeletal sites displaying symptoms.
Hydrocephalus
Early diagnosis with measurement of head circumference,
diagnosis with ultrasound, skull radiographs or computed
tomography (CT) [20]. Ventriculocaval shunt should be
preferred before ventriculoperitoneal shunt due to
reduced ability of resorption in the peritoneal cavity in
mannosidosis (Malm D: personal observation).
Otitis media
Diagnosis is simple and insertion of pressure-equalizing
tubes will reduce the impact of the mechanical compo-
nent of reduced hearing. There is a variety of tubes, and
tubes with long-term stability should be preferred, since
the condition is usually long lasting [29].
Hearing
Diagnosis is made with audiometry in cooperating
patients, but can be difficult in young children and
severely retarded patients. In some cases the brainstem
auditory evoked response (BAER) test measuring brainPage 7 of 10
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tones, can be useful. For speech therapy to be effective,
hearing aids should be provided.
Dental state
Caries seem frequent because of reduced dental quality
combined with tooth grinding or acid reflux from the
stomach. Regular dental support and good dental hygiene
is obviously important.
Joint status
Goniometry is used in the measurement of joint pathol-
ogy. Kyphoscoliosis is measured according to Cobb, and
can be corrected with orthopedic surgery (Fig 2). Genu
valgum deformity can be treated with epiphyseal stapling
in growing children, but must be performed early to be
effective [23].
Mental state
Can be monitored with various tests, such as Wechsler.
Nonverbal tests can compensate for the hearing deficit.
Specific treatment
In α-mannosidosis all cells are devoid of α-mannosidase
activity. Early observations showed that cells producing α-
mannosidase were able to transfer the enzyme to man-
nosidosis cells [63,66]. The rationale for bone marrow
transplantation (BMT) in mannosidosis is that enzyme-
producing donor cells repopulate the host tissues and
transfer enzyme to nearby enzyme-deficient host cells.
In 1987 Will et al. performed BMT in a patient with α-
mannosidosis. However, the patient died 18 weeks after
successful grafting due to procedure related complica-
tions. The post mortem examination showed that trans-
plantation reversed the somatic changes of α-
mannosidosis, but did not affect lysosomal storage within
brain tissue. It was therefore concluded that BMT may not
be a suitable treatment for α-mannosidosis [67]. How-
ever, the findings of nil effect in the brain could be
explained by the only 50% activity in donor cells which
came from the mother (being a carrier of alpha-mannosi-
dosis), the treatment of prednisone which could have
influenced synthesis of protein, or the short observation
period. Because of the blood-brain barrier, the main ques-
tion remained whether BMT could improve the pathology
of the central nervous system. In 1994, Steven Walkley
reported that an early BMT could prevent neurological
deterioration in a cat model [68]. A possible explanation
of the neuronal benefits of BMT could be migration of
donor-derived cells to the CNS of the recipient [69]. Later,
Wall et al. (1998) presented a single case with BMT, claim-
ing complete resolution of the recurrent infectious disease
and organomegaly, improvement in the bone disease, and
stabilization of neurocognitive function during a 2 year
observation period [70].
Subsequently, a number of unpublished BMTs were per-
formed, and in 2004, Grewal et al. could present results
from four patients, aged 3 to 23 years, that had undergone
BMT [69]. In short, they claimed that intellectual function
stabilized, with improvement in adaptive skills and verbal
memory function in 3 of 4 patients. Especially hearing
improved to normal or near normal, but for speech fre-
quencies only.
The possible benefits of BMT must be weighed against the
overall risk of procedure related morbidity and mortality.
The benefits are greater in younger patients before compli-
cations have developed, and also transplant related com-
plications are more frequent and severe in older patients.
Therefore, BMT is an option in the first decade of life
which makes early identification of affected patients criti-
cal.
Prognosis
The long-term prognosis is poor. There is an insidiously
slow progression of neuromuscular and skeletal deteriora-
tion over several decades, making most patients wheel-
chair dependent. No patients manage to be completely
socially independent. Many patients are over 50 years of
age.
Unresolved questions
Enzyme replacement therapy (ERT) is a therapeutic
modality in other lysosomal storage diseases, like Gau-
cher, Fabry or Pompe disease. In α-mannosidosis, experi-
ments with ERT have been performed in an artificial
knock-out mouse model [45], and in a naturally occurring
guinea pig model [71]. The reduction in storage material
was evident in almost all tissues in both models. How-
ever, whereas the first study found a reduction of man-
nose containing oligosaccharides in the brain to less than
30% of that in control mice with α-mannosidosis [45], a
similar cerebral improvement was not found in guinea-
pigs [71]. The development of ERT in human is the long
term objective of the European HUE-MAN project [8].
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